CAR-T Cell Therapy: the Efficacy and Toxicity Balance

被引:0
作者
Karan L. Chohan
Elizabeth L. Siegler
Saad S. Kenderian
机构
[1] Mayo Clinic,Department of Medicine
[2] Mayo Clinic,T Cell Engineering
[3] Mayo Clinic,Division of Hematology
[4] Mayo Clinic,Department of Molecular Medicine
[5] Mayo Clinic,Department of Immunology
[6] Mayo Clinic,Department of Molecular Pharmacology & Experimental Therapeutics
来源
Current Hematologic Malignancy Reports | 2023年 / 18卷
关键词
CAR-T; Immunotherapy; CAR-T toxicity; CAR-T efficacy; CRS; ICANS; CAR-T neurotoxicity;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:9 / 18
页数:9
相关论文
共 137 条
[1]  
Almasbak H(2016)CAR T cell therapy: a game changer in cancer treatment J Immunol Res 2016 5474602-156
[2]  
Aarvak T(2021)CAR-T cell therapy: current limitations and potential strategies Blood Cancer J 11 69-199
[3]  
Vemuri MC(2019)Engineering and design of chimeric antigen receptors Mol Ther Methods Clin Dev 12 145-1121
[4]  
Sterner RC(2018)Universal CARs, universal T cells, and universal CAR T cells J Hematol Oncol 11 132-1365
[5]  
Sterner RM(2020)‘Off-the-shelf’ allogeneic CAR T cells: development and challenges Nat Rev Drug Discov 19 185-2797
[6]  
Guedan S(2016)Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease J Clin Oncol 34 1112-75
[7]  
Calderon H(2018)CAR T cell immunotherapy for human cancer Science 359 1361-5574
[8]  
Posey AD(1998)Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product J Immunol 161 2791-56
[9]  
Maus MV(2002)Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor Nat Biotechnol 20 70-2544
[10]  
Zhao J(2009)A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity J Immunol 183 5563-1342